Correlation Between Sfrp1 Expression and Clinicopathological Parameters in Patients With Triple-Negative Breast Cancer

What is it about?

Triple negative breast cancer (TNBC) is known as the most aggressive breast cancer subtype and is defined by the lack of estrogene, progesterone and human epidermal growth factor receptor 2. Therefore chemotherapy remains as the sole effective treatment option at current state. In this study we show that SFRP1 is strongly associated with TNBC. Furthermore our results support that SFRP1 might predict chemotherapy response in TNBC.

Featured Image